Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discount will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Pharmaceuticals
Juno Therapeutics has acquired RedoxTherapies for $10 million in cash and potential milestone payments. With the deal comes vipadenant, a small-molecule adenosine A2A receptor antagonist that has the potential to inhibit immunosuppressive pathways in cancer. Juno intends to test the molecule in combination with its engineered T-cell candidates. Only a few days before announcing the acquisition, Juno was allowed to restart a Phase II leukemia clinical trial of its lead product candidate, JCAR015. FDA had halted the trial when two patients died after the addition of another drug to the treatment regimen.
This article has been sent to the following recipient: